Loading
Among 71 people with pancreatic cancer and an inherited BRCA mutation, those with advanced disease lived 22 months on platinum chemotherapy against 9 months on other drugs, the clinical hint that led to the POLO trial.
Patients with BRCA1/2-associated pancreatic ductal adenocarcinoma diagnosed 1994 to 2012 were identified at three institutions: 71 patients (BRCA1 21, BRCA2 49, both 1), mean age 60.3, 81.7% with a family history of malignancy, 30% resected. Median overall survival for 58 analysable patients was 14 months; not reached for stage 1/2 (52% alive at 60 months) and 12 months for stage 3/4. Superior overall survival was observed for stage 3/4 patients treated with platinum against non-platinum chemotherapy (22 versus 9 months; P = 0.039).
The retrospective platinum signal that made platinum-based first-line chemotherapy the standard for BRCA carriers and set POLO's design of olaparib after platinum.
Shares Talia Golan, POLO, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA).
Shares Talia Golan, POLO, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA).
Shares POLO, Germline BRCA1/2 pathogenic variant (gBRCAm), Gemcitabine + cisplatin, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma.
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD).
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD).
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD), Metastatic pancreatic ductal adenocarcinoma.
Shares POLO, FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD).